Bavarian Nordic A/S has been awarded a subcontract from Crucell Holland B.V., one of Janssen Pharmaceutical Companies of Johnson & Johnson, valued at $9 million. This is part of a contract awarded to Janssen by the U.S. Biomedical Advanced Research and Development Authority (BARDA) to support the advanced development and manufacturing of the Ebola prime-boost vaccine regimen, which consists of Bavarian Nordic’s MVA-BN Filo and Ad26.ZEBOV from Janssen. The five-year base subcontract ...